| (Values in U.S. Thousands) | Mar, 2026 | Mar, 2025 | Mar, 2024 | Mar, 2023 | Mar, 2022 |
| Sales | 8,260 | 29,050 | 124,800 | 61,280 | 55,290 |
| Sales Growth | -71.57% | -76.72% | +103.66% | +10.83% | +132.31% |
| Net Income | -299,770 | -171,980 | 4,348,930 | -1,009,030 | -845,260 |
| Net Income Growth | -74.31% | -103.95% | +531.00% | -19.38% | -4.45% |
Roivant Sciences Ltd WT (ROIVW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Roivant Sciences is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences, formerly known as Montes Archimedes Acquisition Corp., is based in NEW YORK.
Fiscal Year End Date: 03/31